Michael Wang, MD
The CAR T-cell therapy lisocabtagene maraleucel (liso-cel; JCAR017) elicited a 71% overall response rate (ORR) as well as a tolerable safety profile in a cohort of patients with relapsed/refractory mantle cell lymphoma (MCL), according to results from the TRANSCEND NHL 001 trial that were presented at the 2019 ASCO Annual Meeting.
The ORR consisted of a 53% complete response (CR) rate of 53%, and 7 of the 9 CRs were ongoing as of data cutoff.
"In the ongoing TRANSCEND NHL 001 study, treatment of patients with relapsed/refractory mantle cell lymphoma receiving both dose levels of liso-cel was associated with tolerable toxicity, including a low incidence of grade 3 or 4 cytokine release syndrome and neurotoxicity," the study authors, led by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, wrote in their poster. "Liso-cel showed promising clinical activity in patients with relapsed/refractory mantle cell lymphoma."
... to read the full story